

# EDIT-B<sup>®</sup> Instruction for use

RNA blood test for differential diagnosis of bipolar disorder and unipolar depression

This document present the general instruction for use for EDIT-B<sup>®</sup> test. The detailed protocol to use EDIT-B<sup>®</sup> test is provided in the Handbook available on the EDIT-B<sup>®</sup> Platform.

EDIT-B<sup>®</sup> is not a self-diagnostic test.

EDIT-B<sup>®</sup> is not a companion diagnostic test.

EDIT-B<sup>®</sup> is solely intended to be used by qualified professionals.

<u>Identification of the IVD device</u>	<u>Legal manufactured</u>
Product name: <b>EDIT-B<sup>®</sup></b> Product reference: <b>0100</b>	ALCEDIAG Cap Gamma 1682 rue de la Valsiere 34790 GRABELS FRANCE Email: <a href="mailto:support.edit-b@alcediag-alcen.com">support.edit-b@alcediag-alcen.com</a> Website: <a href="https://www.alcediag-alcen.com">https://www.alcediag-alcen.com</a>

EDIT-B<sup>®</sup> is an in vitro diagnostic medical device CE marked according to the european directive 98/79/CE.



The IFU is available in three languages (FR, EN and IT) in electronic format.

## Table of contents

1. Test description .....	3
Intended use.....	3
Overview of the test.....	3
2. Scientific and technical principles of the test.....	4
3. Terms of use .....	5
4. Precautions for use.....	5
5. Limits of use.....	6
6. Collection and storage of samples.....	6
7. Sample analysis method.....	6
8. EDIT-B® Platform .....	6
9. EDIT-B® test results .....	6
Decision rules for EDIT-B® test results.....	7
EDIT-B® specifications .....	7
10. EDIT-B® clinical performance.....	7
11. Symbols.....	8
12. Relevant warnings and limitations .....	8
13. Abbreviation .....	9
14. Bibliographic references.....	10

## 1. Test description

### *Intended use*

EDIT-B® is a qualitative In Vitro Medical Device (IVD) intended for the differential diagnosis between bipolar disorders and major depressive disorders (unipolar depression).

EDIT-B® combines RNA sequencing technology to measure RNA editing targets (from a panel of biomarkers using whole blood ) and patient individual data (age, sex, treatment(s), consumptions or addiction [tobacco, alcohol])<sup>[1]</sup>.

EDIT-B®'s prescription is exclusively intended for physicians authorized to establish a diagnosis of psychiatric illnesses.

EDIT-B® is part of the diagnostic process for mood disorders, in addition to the usual diagnostic methods, such as the DSM-5 and ICD-11 criteria and clinical scales (MADRS, HDRS, BDI, etc.)<sup>[2, 3]</sup>. The results of the test should complement the clinical and behavioural arguments usually used by the physician to make its final diagnosis.

EDIT-B® is intended to be used on patients aged 18 years and older, male or female, with a current major depressive episode (moderate or severe) and being treated\* for that depression at the moment of the test.

*\*According to ATC classification, five treatment classes are considered: Antiepileptics, Antipsychotics, Anxiolytics, Hypnotics/Sedatives and Antidepressants.*

### *Overview of the test*

From a blood sample collected in a PAXgene® Blood RNA tube at usual collection points, the biological analyses are carried out by medical biology laboratories accredited for RNA sequencing and approved by the company ALCEDIAG.

Then a score calculation is carried out by a software developed by ALCEDIAG, which contains modules for quality control and an algorithm to determine the patient result. The score calculation algorithm is hosted on a SaaS (Software as a Service) type platform, accessible via the website <http://edit-b.alcediag-alcen.com/>. The platform offers dedicated access to medical biology laboratories (access authorization administered by the company ALCEDIAG). It complies with European security, GDPR (General Data Protection Regulation) and health data management standards. The analysis and algorithm calculation processes are patented.

---

## 2. Scientific and technical principles of the test

The biological component of the EDIT-B® test falls under a specific sub-category of molecular biology, called epigenetics. While genetics is the study of genes and heredity, epigenetics focuses on a complementary aspect, in particular how environmental factors turn on/off or regulate genes, and affect gene expression <sup>[4, 5]</sup>. Epigenetic processes are reversible and dynamic, as they evolve over time. They are affected by environmental factors in the broad sense (pathologies, nutrition, physical activity, stress, medication, etc.) <sup>[6, 7]</sup>. Thus, epigenetic biomarkers allow a dynamic approach to diagnosis <sup>[8]</sup>, taking into account the condition of the patients, the potential progression of the disease as well as the impact of treatment <sup>[9, 10]</sup>.

RNA editing is one of the epigenetics phenomena. This is a physiological mechanism that occurs in any individual, and that is – among other factors – influenced by the pathology and/or the medication <sup>[11-13]</sup>. It consists of the substitution, in specific places on the RNA of an adenosine by an inosine, under the specific action of enzymes <sup>[11, 14]</sup>. Several studies have shown that RNA editing is involved in many physiological functions and can affect proteins and regulation mechanisms <sup>[4]</sup>.

One of the most studied processes occurring at the RNA level is the Adenosine to Inosine (A-to-I) deamination, that has been shown to be modified in several neuro-psychiatric disorders. In particular, RNA editing regulates some synaptic functions via an alteration of the functionality of key receptors, leading to a direct impact on synaptic transmission <sup>[15]</sup>. RNA editing is a mechanism linking inflammation and neuropsychiatry <sup>[11, 16-19]</sup>, changes in RNA editing being associated with some mental illnesses (such as depression, suicidal tendencies, etc.), but also with some inflammatory diseases <sup>[20]</sup> and certain cancers <sup>[21]</sup>. ALCEDIAG used targeted RNA sequencing on 8 genes selected through several scientific and clinical studies combined with artificial intelligence <sup>[46-50]</sup>, to objectify and quantify the RNA editing mechanism and to develop a tool for the differential diagnosis of unipolar depression and bipolar disorder <sup>[47]</sup>.

### 3. Terms of use

EDIT-B® must be prescribed by a physician authorized to characterize a depressive episode. The medical prescription must mention general patient information, therapeutic classes of the treatment taken by the patient, and any consumptions or addictions (tobacco/alcohol).

The necessary details to be provided when prescribing are described in the EDIT-B® user manual.

The test must be performed during the depressive episode, subject to the medical consultation.

As an aid of diagnosis, EDIT-B® result brings supplementary data on the patient for the physician.

EDIT-B® is carried out according to a standardized method requiring strict compliance with pre-analytical, analytical and post-analytical procedures, as described in the EDIT-B® protocol provided to the laboratory by ALCEDIAG. To perform the test, the laboratories need to be approved by ALCEDIAG.

### 4. Precautions for use

EDIT-B® pre-analytical precautions:

- The blood sample should be taken soon after the prescription (in the days that follow), to ensure that the patient is still in the same state of depression.
- The laboratory should respect the pre-analytical and analytical recommendations provided in the EDIT-B protocol.

Precautions for interpreting EDIT-B® results for the healthcare professionals:

- A result indicating a unipolar depression profile does not necessarily exclude the presence of bipolar disorder. It is mandatory to establish the diagnosis taking into account all the clinical and biological factors related to the patient, and to maintain regular patient monitoring.
- A result indicating a bipolar disorder profile does not formally mean that the patient is affected with bipolar disorder. It is mandatory to establish the diagnosis taking into account all the clinical and biological factors related to the patient, and to maintain regular patient monitoring.
- In the event of a discrepancy between the EDIT-B® result and other diagnostic tools (DSM-5, ICD-11, MADRS, HDRS, BDI, etc.), it is imperative to refer to the conclusions of the prescriber.
- EDIT-B® cannot replace the clinical diagnosis of the prescriber. The causes of these discrepancies may be of pre-analytical, analytical or post-analytical origin, due to non-compliance with the terms of use of the diagnostic test and/or non-compliance to the protocol and/or associated with the percentages of false positives and false negatives.

## 5. Limits of use

EDIT-B® is not intended for the patient profiles detailed below:

- Patient under the age of 18;
- Patient with manic symptoms;
- Patient with a contraindication to having a blood test.

## 6. Collection and storage of samples

EDIT-B® is performed from a whole blood sample taken in a 2.5 mL PAXgene® Blood RNA tube. Collection of blood samples can be performed at any time of the day.

The sample should be shaken and stored according to the instructions for use of PAXgene® tubes, namely:

- The sample should preferably be stored at -20°C and below.
- If the sample has to be stored at temperatures below -20°C, freeze it first at -20°C for at least 24 hours, then transfer it to a freezer at -70°C or -80°C.

## 7. Sample analysis method

EDIT-B® library preparation protocol is provided to laboratories accredited by ALCEDIAG to perform EDIT-B®.

The Instructions for Use (IFU) of EDIT-B® are intended for the professionals who will perform the test.

EDIT-B® is intended to be used with an automated RNA PAXgene® extraction device, followed by a manual process until the sequencing step.

The EDIT-B® protocol is described in the EDIT-B® Handbook available on the EDIT-B® platform (<http://edit-b.alcediag-alcen.com/>).

## 8. EDIT-B® Platform

The access to the EDIT-B® platform is provided to laboratories accredited by ALCEDIAG to perform EDIT-B® test.

## 9. EDIT-B® test results

At the end of the EDIT-B® test, a medical report consisting of the results provided by the software is sent to the medical biology laboratory via the EDIT-B® platform. The latter will validate this report and then send it to the physician who issued the prescription.

The results are presented as a qualitative result (Bipolar / Unipolar / No result). See decision rules in the following paragraph.

## Decision rules for EDIT-B® test results

EDIT-B® provides an aid to the physician in diagnosing bipolar or unipolar depressed patients.

<u>Outcomes</u>	<u>Description</u>
✓ <b>Bipolar</b>	The RNA editing profile measured by EDIT-B® corresponds to a bipolar patient profile.
✓ <b>Unipolar</b>	The RNA editing profile measured by EDIT-B® corresponds to a unipolar patient profile.
✓ <b>No result</b>	Requirements to run the EDIT-B® test are not fulfilled.

## No Template Control (NTC) (Water quality control)

Water quality control allows the detection of potential contamination or non-specific amplification in the flow cell being analysed.

## EDIT-B® specifications

In order to successfully deliver a diagnostic aid report, the EDIT-B® test must meet several quality criteria and specifications. These criteria are described in the EDIT-B® Handbook.

## 10. EDIT-B® clinical performance

Two prospective clinical studies were performed to determine the clinical performances of EDIT-B®.

Sample type: Whole blood collected with PAXgene® Blood RNA tubes

<b>EDIT-B® performance</b>	<u>Clinical Performance study*</u>
✓ Population size	94
✓ Sensibility (%)	85.7
✓ Specificity (%)	81.8

\*Clinical study carried out with Swiss psychiatric centres, les Toises

## 11. Symbols

Manufacturer: ALCEDIAG, 1682 RUE DE LA VALSIERE, 34790 GRABELS, FRANCE	
Complies with the demands of directive 98/79/CE	
IVD Diagnostic Medical Device	
Catalogue Reference: 0100	
Consult instructions for use	

## 12. Relevant warnings and limitations

	<ul style="list-style-type: none"> <li>• EDIT-B® is not intended for patients with manic symptoms.</li> <li>• This assay is not indicated for stand-alone diagnostic purposes.</li> <li>• This assay is intended to be used during a current major depressive episode (moderate or severe) confirmed by a qualified physician.</li> <li>• Blood collection must be made during the major depressive episode (moderate or severe)</li> <li>• EDIT-B® is intended to be performed by professional users, such as technicians and physicians who are trained in molecular biology</li> </ul>
---	---

---

## 13. Abbreviation

**ATC:** Anatomical Therapeutic Chemical Classification System  
**BDI:** Beck Depression Inventory  
**DSM-V:** Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition  
**EN:** English  
**FASTQ:** Text-based format for storing both a biological sequence and its quality scores  
**FR:** French  
**GDPR:** General Data Protection Regulation  
**HDRS:** Hamilton Depression Rating Scale  
**ICD-11:** International Classification of Diseases eleventh revision  
**IFU:** Instructions for Use  
**IT:** Italian  
**IVD:** In Vitro Diagnostic device  
**MADRS:** Montgomery–Åsberg Depression Rating Scale  
**MAPQ:** MAPping Quality  
**NTC:** No Template Control (water quality control)  
**Phred:** Quality score to measure the quality of the identification of the nucleobases sequenced  
**RNA:** RiboNucleic Acid

## 14. Bibliographic references

1. Vismara, M., et al., *Peripheral Biomarkers in DSM-5 Anxiety Disorders: An Updated Overview*. *Brain Sci*, 2020. **10**(8).
2. Jentsch, M.C., et al., *Biomarker approaches in major depressive disorder evaluated in the context of current hypotheses*. *Biomark Med*, 2015. **9**(3): p. 277-97.
3. Lin, E. and S.J. Tsai, *Epigenetics and Depression: An Update*. *Psychiatry Investig*, 2019. **16**(9): p. 654-661.
4. Garcia-Gimenez, J.L., et al., *Epigenetic biomarkers: Current strategies and future challenges for their use in the clinical laboratory*. *Crit Rev Clin Lab Sci*, 2017. **54**(7-8): p. 529-550.
5. Gatsiou, A., et al., *Adenosine-to-Inosine RNA Editing in Health and Disease*. *Antioxid Redox Signal*, 2018. **29**(9): p. 846-863.
6. Wang, Q., et al., *RNA Editing, ADAR1, and the Innate Immune Response*. *Genes (Basel)*, 2017. **8**(1).
7. Morabito, M.V. and R.B. Emeson, *RNA editing as a therapeutic target for CNS disorders*. *Neuropsychopharmacology*, 2009. **34**(1): p. 246.
8. Jeon, S.W. and Y.K. Kim, *Inflammation-induced depression: Its pathophysiology and therapeutic implications*. *J Neuroimmunol*, 2017. **313**: p. 92-98.
9. Asnis, G.M., et al., *IFN-induced depression: a role for NSAIDs*. *Psychopharmacol Bull*, 2003. **37**(3): p. 29-50.
10. Dowlati, Y., et al., *A meta-analysis of cytokines in major depression*. *Biol Psychiatry*, 2010. **67**(5): p. 446-57.
11. Liu, H., et al., *Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss*. *Nat Med*, 2019. **25**(1): p. 95-102.
12. Rifai, M.A. and M.A. Sabouni, *Utilizing genomic polymorphisms to personalize hepatitis C therapies*. *Curr Opin Organ Transplant*, 2012. **17**(2): p. 198-203.
13. Yoshida, K., et al., *Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings*. *Neuropsychobiology*, 2005. **52**(2): p. 55-61.
14. Avila, M., et al., *Lyn kinase controls TLR4-dependent IKK and MAPK activation modulating the activity of TRAF-6/TAK-1 protein complex in mast cells*. *Innate Immun*, 2012. **18**(4): p. 648-60.
15. O'Neill, M.J., et al., *AMPA receptor potentiators for the treatment of CNS disorders*. *Curr Drug Targets CNS Neurol Disord*, 2004. **3**(3): p. 181-94.
16. Zhang, S.F., et al., *Comparison of cognitive impairments with lipid profiles and inflammatory biomarkers in unipolar and bipolar depression*. *J Psychiatr Res*, 2022. **150**: p. 300-306.
17. Wang, H., et al., *GAB2 regulates type 2 T helper cell differentiation in humans*. *Cytokine*, 2017. **96**: p. 234-237.
18. Reiman, E.M., et al., *GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers*. *Neuron*, 2007. **54**(5): p. 713-20.
19. Hu, Y., et al., *GAB2 rs2373115 variant contributes to Alzheimer's disease risk specifically in European population*. *J Neurol Sci*, 2017. **375**: p. 18-22.
20. Zhu, Z., et al., *Increased expression of PRKCB mRNA in peripheral blood mononuclear cells from patients with systemic lupus erythematosus*. *Ann Hum Genet*, 2018. **82**(4): p. 200-205.
21. Guo, X., et al., *Down-regulation of PRKCB1 expression in Han Chinese patients with subsyndromal symptomatic depression*. *J Psychiatr Res*, 2015. **69**: p. 1-6.
22. Costas, J., et al., *Association study of 44 candidate genes with depressive and anxiety symptoms in post-partum women*. *J Psychiatr Res*, 2010. **44**(11): p. 717-24.
23. Jacobsen, M., et al., *A point mutation in PTPRC is associated with the development of multiple sclerosis*. *Nat Genet*, 2000. **26**(4): p. 495-9.
24. Colledge, M., et al., *Ubiquitination regulates PSD-95 degradation and AMPA receptor surface expression*. *Neuron*, 2003. **40**(3): p. 595-607.
25. Brown, V.K., et al., *Multiple components of the B cell antigen receptor complex associate with the protein tyrosine phosphatase, CD45*. *J Biol Chem*, 1994. **269**(25): p. 17238-44.
26. Tan, J., T. Town, and M. Mullan, *CD45 inhibits CD40L-induced microglial activation via negative regulation of the Src/p44/42 MAPK pathway*. *J Biol Chem*, 2000. **275**(47): p. 37224-31.
27. Aw, E., Y. Zhang, and M. Carroll, *Microglial responses to peripheral type 1 interferon*. *J Neuroinflammation*, 2020. **17**(1): p. 340.
28. Basterzi, A.D., et al., *Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis*. *Prog Neuropsychopharmacol Biol Psychiatry*, 2010. **34**(1): p. 70-5.
29. Yao, Z., et al., *Molecular characterization of the human interleukin (IL)-17 receptor*. *Cytokine*, 1997. **9**(11): p. 794-800.
30. Beurel, E., L.E. Harrington, and R.S. Jope, *Inflammatory T helper 17 cells promote depression-like behavior in mice*. *Biol Psychiatry*, 2013. **73**(7): p. 622-30.
31. Slyepchenko, A., et al., *T helper 17 cells may drive neuroprogression in major depressive disorder: Proposal of an integrative model*. *Neurosci Biobehav Rev*, 2016. **64**: p. 83-100.
32. Rouillard, A.D., et al., *The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins*. *Database (Oxford)*, 2016. **2016**.
33. Chen, Y., et al., *Emerging tendency towards autoimmune process in major depressive patients: a novel insight from Th17*

cells. *Psychiatry Res*, 2011. **188**(2): p. 224-30.

34. Yang, H., et al., Knockdown of zinc finger protein 267 suppresses diffuse large B-cell lymphoma progression, metastasis, and cancer stem cell properties. *Bioengineered*, 2022. **13**(1): p. 1686-1701.
35. Schnabl, B., et al., Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease. *Int J Clin Exp Pathol*, 2011. **4**(7): p. 661-6.
36. Schnabl, B., et al., Zinc finger protein 267 is up-regulated during the activation process of human hepatic stellate cells and functions as a negative transcriptional regulator of MMP-10. *Biochem Biophys Res Commun*, 2005. **335**(1): p. 87-96.
37. Schnabl, B., et al., Zinc finger protein 267 is up-regulated in hepatocellular carcinoma and promotes tumor cell proliferation and migration. *Exp Mol Pathol*, 2011. **91**(3): p. 695-701.
38. Patel, S., et al., Characterization of Human Genes Modulated by *Porphyromonas gingivalis* Highlights the Ribosome, Hypothalamus, and Cholinergic Neurons. *Front Immunol*, 2021. **12**: p. 646259.
39. Bahado-Singh, R.O., et al., Artificial intelligence and placental DNA methylation: newborn prediction and molecular mechanisms of autism in preterm children. *J Matern Fetal Neonatal Med*, 2021: p. 1-10.
40. Hirschfeld, R.M., et al., Screening for bipolar disorder in patients treated for depression in a family medicine clinic. *J Am Board Fam Pract*, 2005. **18**(4): p. 233-9.
41. Fried, E.I., The 52 symptoms of major depression: Lack of content overlap among seven common depression scales. *J Affect Disord*, 2017. **208**: p. 191-197.
42. Salvetat, N., et al., A game changer for bipolar disorder diagnosis using RNA editing-based biomarkers. *Transl Psychiatry*, 2022. **12**(1): p. 182.
43. Schwarz, E., et al., Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation. *World J Biol Psychiatry*, 2012. **13**(8): p. 627-32.
44. Ren, J., et al., Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LC-MS/MS and bioinformatics analysis. *Psychoneuroendocrinology*, 2017. **86**: p. 17-24.
45. Kittel-Schneider, S., et al., Proteomic Profiling as a Diagnostic Biomarker for Discriminating Between Bipolar and Unipolar Depression. *Front Psychiatry*, 2020. **11**: p. 189.
46. Bai, Y.M., et al., A comparison study of metabolic profiles, immunity, and brain gray matter volumes between patients with bipolar disorder and depressive disorder. *J Neuroinflammation*, 2020. **17**(1): p. 42.
47. Sayana, P., et al., A systematic review of evidence for the role of inflammatory biomarkers in bipolar patients. *J Psychiatr Res*, 2017. **92**: p. 160-182.
48. Wollenhaupt-Aguilar, B., et al., Differential biomarker signatures in unipolar and bipolar depression: A machine learning approach. *Aust N Z J Psychiatry*, 2020. **54**(4): p. 393-401.
49. Rajagopalan, A., et al., Digital Platforms in the Assessment and Monitoring of Patients with Bipolar Disorder. *Brain Sci*, 2017. **7**(11).
50. Stanislaus, S., et al., Smartphone-based activity measurements in patients with newly diagnosed bipolar disorder, unaffected relatives and control individuals. *Int J Bipolar Disord*, 2020. **8**(1): p. 32.
51. Dargel, A.A., et al., Toi Meme, a Mobile Health Platform for Measuring Bipolar Illness Activity: Protocol for a Feasibility Study. *JMIR Res Protoc*, 2020. **9**(8): p. e18818.
52. Frye, M.A., et al., Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders. *Transl Psychiatry*, 2015. **5**: p. e689.
53. Nurnberger, J.I., Jr., et al., Identification of pathways for bipolar disorder: a meta-analysis. *JAMA Psychiatry*, 2014. **71**(6): p. 657-64.
54. Kato, T., Whole genome/exome sequencing in mood and psychotic disorders. *Psychiatry Clin Neurosci*, 2015. **69**(2): p. 65-76.
55. Gatt, J.M., et al., Specific and common genes implicated across major mental disorders: a review of meta-analysis studies. *J Psychiatr Res*, 2015. **60**: p. 1-13.
56. Lee, S.Y., et al., Serum miRNA as a possible biomarker in the diagnosis of bipolar II disorder. *Sci Rep*, 2020. **10**(1): p. 1131.
57. Wang, Z., et al., miRNA-206 and BDNF genes interacted in bipolar I disorder. *J Affect Disord*, 2014. **162**: p. 116-9.
58. Liebers, D.T., et al., Discriminating bipolar depression from major depressive disorder with polygenic risk scores. *Psychol Med*, 2021. **51**(9): p. 1451-1458.
59. Polyakova, M., et al., BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis. *J Affect Disord*, 2015. **174**: p. 432-40.
60. Idemoto, K., et al., Platelet-derived growth factor BB: A potential diagnostic blood biomarker for differentiating bipolar disorder from major depressive disorder. *J Psychiatr Res*, 2021. **134**: p. 48-56.
61. Stamm, S., et al., The activity of the serotonin receptor 2C is regulated by alternative splicing. *Hum Genet*, 2017. **136**(9): p. 1079-1091.

End of document

## Document history

### Review and approval

	<b>Redaction</b>	<b>Verification</b>	<b>Approbation</b>
<b>Nom</b>	Manon Aigle	Benjamin Dubuc	Dinah Weissmann
<b>Date</b>			
<b>Visa</b>			

### Revision history

<b>Versions</b>	<b>Date</b>	<b>Modifications</b>
1.0	2022/03/17	Initial document
1.1	2022/05/10	Update of the IFU
1.2	2023/01/09	Update of the IFU following the CC-SMQ-001
1.3	2023/12/16	Update with EDIT-B specifications et clinical performance Layout update
1.4	2024/05/28	Minor correction regarding the contact address for support.
1.5	2024/06/19	Section 1 Reformulation of the indication Section 2 Removal of the asterisk presenting the 8 targets Section 3 Deletion of details to be put on the prescription and reference to the user manual Section 9 Updated NTC paragraph and removed test specifications by referring to user manual Section 10 Correction of the number of patients affected by the second study in the clinical performance table
1.6	2024/07/16	Section 10: Deletion of clinical results of the cohort 1. Add section 11 Symbols and 12 Relevant warnings and limitations